Thus, in the context of PAH, neutralizing IL-1β, inhibiting IL-1β signaling, or inhibiting the upstream pathways that govern IL-1β release may be effective for mitigating disease progression. This evidence concerns the gene IL1B and pulmonary arterial hypertension.